| Antigen: |
HPV-18 E6 (early protein E6) |
| Relevance: |
The human papilloma virus
(HPV) family of DNA tumor viruses includes HPV-16 and
HPV-18, which are associated with a large proportion
of cervical cancer cases. HPV early proteins E6 and
E7 are the major viral oncoproteins that regulate cell
proliferation through the inactivation of p53 and Rb1
tumour suppressor proteins respectively. BF7 can be
used for detection of HPV in cervical smears and biopsies
and analysis of E6 expression in cell transformation
studies. |
| Clone: |
BF7 |
| Subclass: |
IgG1 |
| Applications: |
Immunohistochemistry, Western blot, Radioimmunoassay, ELISA |
| Immunogen: |
Gel-purified HPV-18 E6-β-galactosidase
fusion protein |
| Reactivity: |
- |
| Species raised in: |
Mouse: Balb/c |
| Fusion partner: |
NS-1 |
| Recommended growth conditions: |
DMEM 5%FCS |
| References: |
- |
| Notes: |
A 16.5 kDa MW polypeptide in cells derived from a human cervical carcinoma. Positive control: any infected tissue. |
For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com
Please note that CRT supplies to distributors only. However, we are happy to direct researchers to the appropriate commercial party to obtain antibodies within our portfolio. Click here to view disclaimer information. |
